Back to search
FDAFDA · Food and drugs·Recall number D-0471-2026

Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR

Published April 22, 2026 · Recall initiated: March 6, 2026

Summary

FDA records drug Class II recall D-0471-2026, published April 22, 2026 and initiated March 6, 2026. Recalling firm: PAYLESS COMPOUNDERS, LLC; Status: Ongoing; Reported quantity: 91 vials; Lot: Lot Number 01-27-2026@14S.5. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
PAYLESS COMPOUNDERS, LLC
Distributor
OR
Lot
Lot Number 01-27-2026@14S.5
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR recalled?

Yes. FDA published recall D-0471-2026 on April 22, 2026. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter